Briacell Therapeutics Corp (BCTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $29.60M
Last updated: Nov 17, 2026 at 4:37 PM ET
Briacell Therapeutics Corp (BCTX) Statistics
Briacell Therapeutics (BCTX) has a market cap of $29.60M and an enterprise value of $19.75M. It kept -13771.38% of revenue as net income over the last 12 months. Its share count is up 1843.48% from a year earlier.
Total Valuation
Enterprise value is 33.28% below the market cap, as cash exceeds debt.
| Market Cap | $29.60M |
|---|---|
| Enterprise Value | $19.75M |
| Latest price (Nov 17, 2026) | $3.51 |
Key Dates
The next earnings report is expected on Dec 10, 2026, covering the quarter ending Oct 31, 2026.
| Next Earnings Date | Dec 10, 2026 (expected) |
|---|---|
| Last Earnings Date | Oct 28, 2026 |
| Fiscal Year End | July |
Valuation Ratios
| Forward P/S | 2.9x |
|---|---|
| P/B Ratio | 1.1x |
| P/TBV Ratio | 1.1x |
Price Statistics
The stock is down 61.70% over 52 weeks and trades 5.39% below its 50-day average.
| Beta (1Y) | 1.57 |
|---|---|
| 52-Week Change | -61.70% |
| 1-Month Change | +3.85% |
| 3-Month Change | -11.36% |
| 5-Year Change | -99.74% |
| 10-Year Change | -99.96% |
| Total Return (1Y) | -61.70% |
| Total Return (3Y CAGR) | -82.47% |
| Total Return (5Y CAGR) | -70.31% |
| Return vs SPY (1Y) | -65.92% |
| Max Drawdown (1Y) | -78.32% |
| Max Drawdown (3Y) | -99.69% |
| Sharpe Ratio (1Y) | -0.63 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $3.71 |
| 200-Day Average | $3.75 |
| 52-Week Range | $2.60 to $13.09 |
| RSI (14 Days) | 49.6 |
| Average Volume (20 Days) | 65.43K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.76x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.76x |
|---|---|
| Quick Ratio | 2.76x |
| Debt / Equity | 0.00x |
Scores
BCTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue of $225.34K over the last 12 months is up 893.96% from the 12 months before.
| Revenue | $225.34K |
|---|---|
| Revenue Growth (YoY) | +893.96% |
| Gross Profit | -$63.57K |
| Operating Income | -$32.17M |
| Pretax Income | -$31.10M |
| Net Income | -$31.03M |
| Reported EPS (TTM) | -$9.16 |
Trailing 12 months through Apr 30, 2026.
Balance Sheet
Shareholder equity funds 69.55% of the $23.58M in total assets.
| Cash and Equivalents | $9.85M |
|---|---|
| Total Debt | $0 |
| Net Cash | $9.85M |
| Net Cash Per Share | $1.97 |
| Working Capital | $14.06M |
| Shareholder Equity | $16.40M |
| Book Value Per Share | $3.27 |
| Tangible Book Value | $16.23M |
| Tangible Book Per Share | $3.24 |
| Total Assets | $23.58M |
| Total Liabilities | $8.02M |
Balance sheet as of Jul 31, 2026.
Cash Flow
| Operating Cash Flow | -$28.71M |
|---|---|
| FCF Per Share | -$3.31 |
| Depreciation and Amortization | $119.33K |
Trailing 12 months through Jul 31, 2026.
Margins
The operating margin is -14274.44%.
| Gross Margin | -28.21% |
|---|---|
| Operating Margin | -14274.44% |
| Pretax Margin | -13803.30% |
| Net Margin | -13771.38% |
Stock Splits
The last split was a 1-for-10 reverse split on Aug 25, 2025.
| Last Split Date | Aug 25, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BCTX
What is BCTX's market cap?
Briacell Therapeutics has a market cap of $29.60M. Its enterprise value, which adds debt and subtracts cash, is $19.75M.
How many shares of BCTX are outstanding?
Briacell Therapeutics has 5.01M shares outstanding. The count is up 1843.48% from a year earlier.
Does BCTX pay a dividend?
No. Briacell Therapeutics does not pay a dividend.
How much debt does BCTX have?
Briacell Therapeutics has $0 of total debt and $9.85M of cash and equivalents, a net cash position of $9.85M.
BCTX pages: Overview, Charting, Earnings, Financials, Statistics, Competitors